A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques

• DOI: 10.1126/sciadv.aba8399
• Publication Date: 2020-05-01T23:11:19Z
• Authors: Neeltje van Dorem...; Elaine Haddock; Friederike Feldmann; Kimberly Meade-White; Trenton Bushmaker; Robert J. Fischer; Atsushi Okumura; Patrick W. Hanley; Greg Saturday; Nick J. Edwards; Madeleine H. A. C...; Teresa Lambe; Sarah C. Gilbert; Vincent J. Munster
• Keywords: Male; 0301 basic medicine; Dipeptidyl Peptidase 4; Pneumonia, Viral; Mice, Transgenic; Antibodies, Viral; Injections, Intramuscular; Severity of Illness Index; Mice; 03 medical and health sciences; Immunogenicity, Vaccine; Vaccines, DNA; Animals; Humans; Research Articles; Multidisciplinary; Vaccination; Viral Vaccines; Antibodies, Neutralizing; Macaca mulatta; 3. Good health; Treatment Outcome; Middle East Respiratory Syndrome Coronavirus; Female; Coronavirus Infections

Developing a vaccine to protect against the lethal effects of many strains coronavirus is critical given current global pandemic. For Middle East respiratory syndrome (MERS-CoV), we show that rhesus macaques seroconverted rapidly after single intramuscular vaccination with ChAdOx1 MERS. The protected injury and pneumonia reduced viral load in lung tissue by several orders magnitude. MERS-CoV replication type I II pneumocytes MERS-vaccinated animals was absent. A prime-boost regimen MERS boosted antibody titers, completely absent from tract these macaques. We also found antibodies elicited neutralized six different strains. Transgenic human dipeptidyl peptidase 4 mice vaccinated were disease lethality for all data support further clinical development